313 related articles for article (PubMed ID: 30830867)
61. Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy.
Sai B; Xiang J
J Cell Mol Med; 2018 Dec; 22(12):5776-5786. PubMed ID: 30255991
[TBL] [Abstract][Full Text] [Related]
62. FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.
Mori A; Masuda K; Ohtsuka H; Shijo M; Ariake K; Fukase K; Sakata N; Mizuma M; Morikawa T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Fujishima F; Unno M
Cancer Sci; 2018 Dec; 109(12):3883-3895. PubMed ID: 30302867
[TBL] [Abstract][Full Text] [Related]
63. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Urick ME; Bell DW
Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
[TBL] [Abstract][Full Text] [Related]
64. Relationship Between Hematogenous Tumor Cell Dissemination and Cellular Immunity in DCIS Patients.
Gruber IV; Hartkopf AD; Hahn M; Taran FA; Staebler A; Wallwiener D; Brucker SY; Hanke J; Fehm T
Anticancer Res; 2016 May; 36(5):2345-51. PubMed ID: 27127142
[TBL] [Abstract][Full Text] [Related]
65. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
[TBL] [Abstract][Full Text] [Related]
66. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S; Cristofanilli M; Singh B; Reuben J; Gao H; Cohen EN; Andreopoulou E; Hall CS; Lodhi A; Jackson S; Lucci A
Cancer; 2010 Jul; 116(14):3330-7. PubMed ID: 20564098
[TBL] [Abstract][Full Text] [Related]
67. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.
Wang Y; Liu Z; Yao B; Li Q; Wang L; Wang C; Dou C; Xu M; Liu Q; Tu K
Mol Cancer; 2017 Jul; 16(1):123. PubMed ID: 28716020
[TBL] [Abstract][Full Text] [Related]
68. Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR.
Luo XL; Deng CC; Su XD; Wang F; Chen Z; Wu XP; Liang SB; Liu JH; Fu LW
Cancer Res; 2018 Jul; 78(13):3532-3543. PubMed ID: 29735544
[TBL] [Abstract][Full Text] [Related]
69. Retrieval of Disseminated Tumor Cells Colonizing the Bone in Murine Breast Cancer Metastasis Models.
Welte T; Yu C; Zhang XH
J Mammary Gland Biol Neoplasia; 2015 Dec; 20(3-4):103-8. PubMed ID: 26490041
[TBL] [Abstract][Full Text] [Related]
70. Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.
Cackowski FC; Wang Y; Decker JT; Sifuentes C; Weindorf S; Jung Y; Wang Y; Decker AM; Yumoto K; Szerlip N; Buttitta L; Pienta KJ; Morgan TM; Taichman RS
Prostate; 2019 Oct; 79(14):1715-1727. PubMed ID: 31449673
[TBL] [Abstract][Full Text] [Related]
71. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model.
Hanania EG; Deisseroth AB
Clin Cancer Res; 1997 Feb; 3(2):281-6. PubMed ID: 9815684
[TBL] [Abstract][Full Text] [Related]
72. MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
Zhao J; Wang Y; Mu C; Xu Y; Sang J
Oncogene; 2017 Aug; 36(35):5023-5034. PubMed ID: 28459460
[TBL] [Abstract][Full Text] [Related]
73. Cytotoxicity of Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7 through inhibition of Tau.
Lin H; Zheng L; Li S; Xie B; Cui B; Xia A; Lin Z; Zhou P
Phytother Res; 2018 Apr; 32(4):667-671. PubMed ID: 29368408
[TBL] [Abstract][Full Text] [Related]
74. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
75. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
Amith SR; Wilkinson JM; Baksh S; Fliegel L
Oncotarget; 2015 Jan; 6(2):1262-75. PubMed ID: 25514463
[TBL] [Abstract][Full Text] [Related]
76. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer.
Hu JL; Wang W; Lan XL; Zeng ZC; Liang YS; Yan YR; Song FY; Wang FF; Zhu XH; Liao WJ; Liao WT; Ding YQ; Liang L
Mol Cancer; 2019 May; 18(1):91. PubMed ID: 31064356
[TBL] [Abstract][Full Text] [Related]
77. Disseminated Tumor Cells and Dormancy in Breast Cancer Progression.
Banys-Paluchowski M; Reinhardt F; Fehm T
Adv Exp Med Biol; 2020; 1220():35-43. PubMed ID: 32304078
[TBL] [Abstract][Full Text] [Related]
78. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
79. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.
Khongkow M; Olmos Y; Gong C; Gomes AR; Monteiro LJ; Yagüe E; Cavaco TB; Khongkow P; Man EP; Laohasinnarong S; Koo CY; Harada-Shoji N; Tsang JW; Coombes RC; Schwer B; Khoo US; Lam EW
Carcinogenesis; 2013 Jul; 34(7):1476-86. PubMed ID: 23514751
[TBL] [Abstract][Full Text] [Related]
80. FBXW7 regulates a mitochondrial transcription program by modulating MITF.
Abbate F; Badal B; Mendelson K; Aydin IT; Serasinghe MN; Iqbal R; Mohammed JN; Solovyov A; Greenbaum BD; Chipuk JE; Celebi JT
Pigment Cell Melanoma Res; 2018 Sep; 31(5):636-640. PubMed ID: 29665239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
